<乌鸦传媒>Mixed Message for Ultrasound in High-Risk Cutaneous Head and Neck Cancer Nodal metastasis detected more often than by clinical exam, worrisome false-positive rate Mar 18, 2022
<乌鸦传媒>FDA OKs PARP Inhibitor as Adjuvant Therapy in Early Breast Cancer Olaparib (Lynparza) approved for high-risk patients with germline BRCA mutations Mar 14, 2022
<乌鸦传媒>Fluorescence-Guided Lumpectomy Shows Promise Imaging system reduced the need for re-excision in one-fifth of patients Mar 11, 2022
<乌鸦传媒>More Research Needed on Use of Premium Cigars, Report Finds These cigars seem less dangerous than cigarettes -- but it's only because of how they are smoked Mar 10, 2022
<乌鸦传媒>Fecal Microbiome Markers Detect Pancreatic Cancer With 'High Accuracy' These markers need to be tested in a prospective cohort before clinical impact can be determined Mar 10, 2022
<乌鸦传媒>Robotic Hepatectomy Shows Benefits Over Laparoscopic Surgery Shorter hospital stay, similar perioperative outcomes in matched analysis Mar 10, 2022
<乌鸦传媒>Radioiodine for Low-Risk Thyroid Cancer: Yea or Nay? Randomized study finds no meaningful difference in events of abnormalities between groups Mar 09, 2022
<乌鸦传媒>Another Casualty of COVID-19: Evidence-Based Medicine Physician laments decline in research quality, critical appraisal during pandemic Mar 09, 2022
<乌鸦传媒>Androgen Receptor Agonist Active in Resistant ER+ Breast Cancer Also: Combination targets uncommon form of advanced HER2-mutant disease Mar 09, 2022
<乌鸦传媒>Is ctDNA Useful for Surveillance in Resected CRC? Small study suggests no advantage compared to imaging alone or with CEA measurement Mar 08, 2022
<乌鸦传媒>More Options for Precision Medicine in Metastatic Triple-Negative Breast Cancer Moving beyond chemotherapy to immunotherapy, PARP inhibitors, ADCs, combinations Mar 08, 2022
<乌鸦传媒>9/11 Responders More Likely to Carry Genetic Mutations Tied to Cancer Clonal hematopoiesis seen in 10% of firefighters, medical personnel on the scene after WTC attack Mar 07, 2022
<乌鸦传媒>Chipping Away at the Dogma of Axillary Dissection in Breast Cancer Ongoing trials could help some women avoid even less-invasive sentinel lymph node biopsy Mar 07, 2022
<乌鸦传媒>Clinical Picture Brightens for HER2+ Breast Cancer With Brain Metastases New therapies breach blood-brain barrier to improve response, survival Mar 07, 2022
<乌鸦传媒>Honing the Indications for Adjuvant CDK4/6 Inhibition in Breast Cancer Defining high risk, considering role of Ki-67, BRCA mutations Mar 05, 2022
<乌鸦传媒>Check Troponin in RCC Patients Before Checkpoint-VEGFR Inhibitor Combo In JAVELIN Renal 101, those with high levels had more heart events with avelumab-axitinib Mar 05, 2022
<乌鸦传媒>Cancer May Heighten Odds of Guillain-Barre Syndrome Link strongest with hematologic malignancies as well as prostate, breast, and respiratory cancers Mar 03, 2022
<乌鸦传媒>ARB-Cancer Link May Come Down to Cumulative Exposure Does a new paper resolve the conflicting safety data on the popular antihypertensives? Mar 02, 2022
<乌鸦传媒>Kids With IBD Need Close Monitoring as They Grow Up Meta-analysis confirms: substantially increased cancer risk in adulthood Mar 02, 2022
<乌鸦传媒>Novel Therapies Active in Head and Neck Cancers High response rate with oncolytic virus plus immunotherapy in cutaneous lesions Feb 28, 2022
<乌鸦传媒>AI Platform Near Perfect for Predicting Thyroid Malignancy High precision for T stage, extracapsular extension, BRAF mutation Feb 27, 2022
<乌鸦传媒>Merkel Cell Carcinoma Much More Likely to Recur vs Other Skin Cancers 5-year recurrence rate was 40% compared with 19% for melanoma Feb 23, 2022
<乌鸦传媒>PD-L1 Inhibitor Fails to Meet PFS Target in Advanced Penile Cancer Atezolizumab did show some activity, with a 30% overall response rate Feb 22, 2022
<乌鸦传媒>Enfortumab Vedotin Promising in Neovadjuvant Therapy in Advanced Bladder Cancer Early-phase study offers 36% pCR in cisplatin-ineligible patients with muscle-invasive disease Feb 19, 2022
<乌鸦传媒>Enzalutamide Rechallenge Yields Small PFS Boost in Metastatic Prostate Cancer Docetaxel-enzalutamide regimen may offer another option for men who progressed on AR inhibitor Feb 18, 2022
<乌鸦传媒>Two PARP Inhibitors Impress as First-Line Add-Ons in mCRPC In one case, rPFS benefit was seen regardless of HRR mutational status Feb 18, 2022
<乌鸦传媒>Ablating High-Grade Anal Lesions Thwarts Progression to Cancer Screening followed by aggressive therapy shows benefit in phase III ANCHOR study Feb 17, 2022
<乌鸦传媒>Darolutamide Improves OS in Metastatic Prostate Cancer The AR inhibitor plus standard therapy led to a 32% reduced risk of death versus placebo Feb 17, 2022
<乌鸦传媒>Early Clinical Activity With CDK4/6 Inhibitor in Pretreated Mesothelioma Disease control in 54% of patients in first clinical evaluation of abemaciclib Feb 17, 2022
<乌鸦传媒>Sotorasib Impresses in Advanced Pancreatic Cancer ORR of 21% in heavily pretreated patients with a KRAS G12C mutation Feb 16, 2022
<乌鸦传媒>Third Person 'Cured' of HIV via Transplant U.S. woman with leukemia gets cord blood resistant to HIV Feb 16, 2022
<乌鸦传媒>Long-Term Survival Benefit in NSCLC With Another Anti-PD-1/L1 Drug Significant improvements in OS, PFS with durvalumab after CRT for unresectable disease Feb 15, 2022
<乌鸦传媒>Women More Likely to Experience Severe Toxicity of Cancer Treatments Increased risk was particularly pronounced among those receiving immunotherapy Feb 14, 2022
<乌鸦传媒>Pembrolizumab Shows Promise in Advanced Anal Cancer PD-1 inhibitor may be an option for those who have no options Feb 11, 2022
<乌鸦传媒>Active Cellular Immunotherapy Disappoints in Metastatic Prostate Cancer In combination with chemotherapy, no OS benefit seen with DCVAC/PCa over placebo Feb 10, 2022
<乌鸦传媒>Illusionist Criss Angel's Son's Acute Leukemia Famed magician speaks about the long battle Feb 09, 2022
<乌鸦传媒>Uterine Cancer Mortality Now Neck and Neck With Ovarian Cancer Advances in ovarian cancer, stagnation in uterine cancer, and "alarming" racial disparity Feb 09, 2022
<乌鸦传媒>Did Improved Treatment for Cervical Abnormalities Affect Birth Outcomes? Swedish data found risks for adverse outcomes remain higher, but declined over time Feb 07, 2022
<乌鸦传媒>Dear Blood Donors, You've Given Me the Gift of Life I offer my gratitude through acceptance, acknowledgement, and reflection Feb 06, 2022
<乌鸦传媒>FDA Concerned About Safety of Lymphoma Drug Hint of excess mortality in trial of umbralisib/ublituximab prompts public notice Feb 03, 2022
